Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	10/12/2013 2:55:25 PM
	Read Replies (2) of 2344

I'd have preferred that onty head in this direction with pet-lipid A, rather than in-license yet another molecule...... clinicaltrials.gov (Perhaps oversimplifying, BCG is thought to be a tlr2/4 agonist.) I was warned by a close friend, and there's a guy at twitter/I.V. who also put it out there, clearly and with spotlight.... this company is very poorly managed. They were scrambling to in-license while talking up 866. Next came a presentation where 866 wasn't even discussed. Most obvious bait and switch I've ever witnessed/swallowed, just so tacky. Believing that, I'm outta here. Thank you, Merck. Nice meeting the crew from I.V. Best of luck, all!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next